Janux Therapeutics JANX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Janux Therapeutics (JANX) reported accretion (amortization) of discounts and premiums, investments of $2.62M in Q1 2026.
- How has Janux Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Janux Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 37.8% year-over-year, from $4.22M to $2.62M.
- What is the long-term trend for Janux Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Janux Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 217.9% compound annual growth rate (CAGR), from $172K to $17.57M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the gradual recognition of the difference between the purchase price and the face value of an investment over its holding period. This adjustment is critical for reconciling net income with actual cash flows from operating activities.